The aim of the present study was to provide early evidence that a biosensor test had the necessary sensitivity and reproducibility for clinical utility and that this test could provide proof-of-concept that some breast cancers classified as HER2− by IHC may exhibit abnormally elevated HER2 activity. This evidence concerns the gene ERBB2 and breast cancer.